An inherited disorder due to defective reabsorption of CYSTINE and other BASIC AMINO ACIDS by the PROXIMAL RENAL TUBULES. This form of aminoaciduria is characterized by the abnormally high urinary levels of cystine; LYSINE; ARGININE; and ORNITHINE. Mutations involve the amino acid transport protein gene SLC3A1.
Amino acid transporter systems capable of transporting basic amino acids (AMINO ACIDS, BASIC).
A covalently linked dimeric nonessential amino acid formed by the oxidation of CYSTEINE. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.
Low-density crystals or stones in any part of the URINARY TRACT. Their chemical compositions often include CALCIUM OXALATE, magnesium ammonium phosphate (struvite), CYSTINE, or URIC ACID.
Stones in the URINARY BLADDER; also known as vesical calculi, bladder stones, or cystoliths.
A country in northern Africa, bordering the Mediterranean Sea, between Egypt, Tunisia, and Algeria, having southern border with Chad, Niger, and Sudan. Its capital is Tripoli.
A group of inherited kidney disorders characterized by the abnormally elevated levels of AMINO ACIDS in URINE. Genetic mutations of transport proteins result in the defective reabsorption of free amino acids at the PROXIMAL RENAL TUBULES. Renal aminoaciduria are classified by the specific amino acid or acids involved.
Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.
Amino acid transporter systems capable of transporting neutral amino acids (AMINO ACIDS, NEUTRAL).
Diamino acids are a type of modified amino acids containing two amino groups, which can be found in various biological molecules and play important roles in various cellular processes, such as nitrogen fixation and protein synthesis.
Formation of stones in any part of the URINARY TRACT, usually in the KIDNEY; URINARY BLADDER; or the URETER.
An autosomal recessive disorder due to defective absorption of NEUTRAL AMINO ACIDS by both the intestine and the PROXIMAL RENAL TUBULES. The abnormal urinary loss of TRYPTOPHAN, a precursor of NIACIN, leads to a NICOTINAMIDE deficiency, PELLAGRA-like light-sensitive rash, CEREBELLAR ATAXIA, emotional instability, and aminoaciduria. Mutations involve the neurotransmitter transporter gene SLC6A19.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Hand-held tools or implements used by health professionals for the performance of surgical tasks.
The taking of a blood sample to determine its character as a whole, to identify levels of its component cells, chemicals, gases, or other constituents, to perform pathological examination, etc.

Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. (1/77)

We identified an amino acid transporter that is associated with the cystinuria-related type II membrane glycoprotein, rBAT (related to b(0,+) amino acid transporter). The transporter designated BAT1 (b(0, +)-type amino acid transporter 1) from rat kidney was found to be structurally related to recently identified amino acid transporters for system L, system y(+)L, and system x(-)C, which are linked, via a disulfide bond, to the other type II membrane glycoprotein, 4F2hc (4F2 heavy chain). In the nonreducing condition, a 125-kDa band, which seems to correspond to the heterodimeric complex of BAT1 and rBAT, was detected in rat kidney with anti-BAT1 antibody. The band was shifted to 41 kDa in the reducing condition, confirming that BAT1 and rBAT are linked via a disulfide bond. The BAT1 and rBAT proteins were shown to be colocalized in the apical membrane of the renal proximal tubules where massive cystine transport had been proposed. When expressed in COS-7 cells with rBAT, but not with 4F2hc, BAT1 exhibited a Na(+)-independent transport of cystine as well as basic and neutral amino acids with the properties of system b(0,+). The results from the present investigation were used to establish a family of amino acid transporters associated with type II membrane glycoproteins.  (+info)

Cloning and expression of a b(0,+)-like amino acid transporter functioning as a heterodimer with 4F2hc instead of rBAT. A new candidate gene for cystinuria. (2/77)

We have cloned a transporter protein from rabbit small intestine, which, when coexpressed with the 4F2 heavy chain (4F2hc) in mammalian cells, induces a b(0,+)-like amino acid transport activity. This protein (4F2-lc6 for the sixth member of the 4F2 light chain family) consists of 487 amino acids and has 12 putative transmembrane domains. At the level of amino acid sequence, 4F2-lc6 shows significant homology (44% identity) to the other five known members of the 4F2 light chain family, namely LAT1 (4F2-lc1), y(+)LAT1 (4F2-lc2), y(+)LAT2 (4F2-lc3), xCT (4F2-lc4), and LAT2 (4F2-lc5). The 4F2hc/4F2-lc6 complex-mediated transport process is Na(+)-independent and exhibits high affinity for neutral and cationic amino acids and cystine. These characteristics are similar to those of the b(0,+)-like amino acid transport activity previously shown to be associated with rBAT (protein related to b(0,+) amino acid transport system). However, the newly cloned 4F2-lc6 does not interact with rBAT. This is the first report of the existence of a b(0,+)-like amino acid transport process that is independent of rBAT. 4F2-lc6 is expressed predominantly in the small intestine and kidney. Based on the characteristics of the transport process mediated by the 4F2hc/4F2-lc6 complex and the expression pattern of 4F2-lc6 in mammalian tissues, we suggest that 4F2-lc6 is a new candidate gene for cystinuria.  (+info)

Luminal heterodimeric amino acid transporter defective in cystinuria. (3/77)

Mutations of the glycoprotein rBAT cause cystinuria type I, an autosomal recessive failure of dibasic amino acid transport (b(0,+) type) across luminal membranes of intestine and kidney cells. Here we identify the permease-like protein b(0,+)AT as the catalytic subunit that associates by a disulfide bond with rBAT to form a hetero-oligomeric b(0,+) amino acid transporter complex. We demonstrate its b(0,+)-type amino acid transport kinetics using a heterodimeric fusion construct and show its luminal brush border localization in kidney proximal tubule. These biochemical, transport, and localization characteristics as well as the chromosomal localization on 19q support the notion that the b(0,+)AT protein is the product of the gene defective in non-type I cystinuria.  (+info)

Identification of five novel SLC3A1 (rBAT) gene mutations in Japanese cystinuria. (4/77)

Identification of five novel SLC3A1 (rBAT) gene mutations in Japanese cystinuria. BACKGROUND: Cystinuria is an inheritable amino aciduria and has been classified into three subtypes: I, II, and III. One of the genes responsible for cystinuria has recently been identified as SLC3A1 or rBAT, but only type I cystinuria seems to be caused by genetic alterations in rBAT. To our knowledge, thus far 38 mutations in rBAT gene have been described. In this study, we investigated rBAT mutations in Japanese patients and compared the results with the previously reported mutations in other races. METHODS: We investigated 36 Japanese cystinuria patients by mutational analysis of rBAT gene. To identify newly mutated alleles, genomic DNA was analyzed by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP). When an abnormal migration was observed on SSCP, a nucleotide sequence determination was performed. RESULTS: Five novel mutations were identified in five patients, three with missense mutations (L346P, I445T, C673R), one with a 1 bp deletion (1820delT), and one with a 2 bp insertion (1898insTA), and we detected three previously reported polymorphisms. Three of the mutations were homozygous, in whom parents had intermarried, and two were heterozygous for each mutations. Analysis of rBAT in family of the 1898insTA patient revealed that the patient had inherited the mutated allele from his parents. CONCLUSION: Five novel mutations in the rBAT gene have been identified in Japanese patients with cystinuria. A racial difference was not apparent in the position and frequency of the mutations.  (+info)

Functional analysis of mutations in SLC7A9, and genotype-phenotype correlation in non-Type I cystinuria. (5/77)

Cystinuria (OMIM 220100) is a common recessive disorder of renal reabsorption of cystine and dibasic amino acids that results in nephrolithiasis of cystine. Mutations in SLC3A1, which encodes rBAT, cause Type I cystinuria, and mutations in SLC7A9, which encodes a putative subunit of rBAT (b(o,+)AT), cause non-Type I cystinuria. Here we describe the genomic structure of SLC7A9 (13 exons) and 28 new mutations in this gene that, together with the seven previously reported, explain 79% of the alleles in 61 non-Type I cystinuria patients. These data demonstrate that SLC7A9 is the main non-Type I cystinuria gene. Mutations G105R, V170M, A182T and R333W are the most frequent SLC7A9 missense mutations found. Among heterozygotes carrying these mutations, A182T heterozygotes showed the lowest urinary excretion values of cystine and dibasic amino acids. Functional analysis of mutation A182T after co-expression with rBAT in HeLa cells revealed significant residual transport activity. In contrast, mutations G105R, V170M and R333W are associated to a complete or almost complete loss of transport activity, leading to a more severe urinary phenotype in heterozygotes. SLC7A9 mutations located in the putative transmembrane domains of b(o,+)AT and affecting conserved amino acid residues with a small side chain generate a severe phenotype, while mutations in non-conserved residues give rise to a mild phenotype. These data provide the first genotype-phenotype correlation in non-Type I cystinuria, and show that a mild urinary phenotype in heterozygotes may associate with mutations with significant residual transport activity.  (+info)

Familial hyperargininaemia. (6/77)

A third case of hyperargininaemia occurring in one family was studied from birth. In cord blood serum arginine concentration was only slightly raised, but arginase activity in red blood cell haemolysates was very low. In the urine on day 2 a typical cystinuria pattern was present. Arginine concentration in serum increased to 158 mumol/100 ml on the 41st day of life. Later determinations of the arginase activity in peripheral blood showed values below the sensitivity of the method. Blood ammonia was consistently high, and cystinuria was present. The enzymatic defect was further displayed by intravenous loading tests with arginine. Serum urea values were predominantly normal or near the lower limit of normal, suggesting the presence of other metabolic pathways of urea synthesis. In urine there was no excretion of guanidinosuccinic acid, while the excretion of other monosubstituted guanidine derivatives was increased, pointing to a connexion with hyperargininaemia. Owing to parental attitude, a low protein diet (1-5 g/kg) was introduced only late. The infant developed severe mental retardation, athetosis, and spasticity.  (+info)

Cystinuria type I: identification of eight new mutations in SLC3A1. (7/77)

BACKGROUND: Cystinuria is a heritable disorder of amino acid transport characterized by the defective transport of cystine and the dibasic amino acids through the brush border epithelial cells of the renal tubule and intestine tract. Three types of cystinuria (I, II, and III) have been described based on the urinary excretion of cystine and dibasic amino acids in obligate heterozygotes. The SLC3A1 gene coding for an amino acid transporter named rBAT is responsible for type I cystinuria, whereas the SLC7A9 gene coding for a subunit (b0,+AT) of rBAT is involved in determining non-type I (types II and III) cystinuria. METHODS: The SLC3A1 gene sequence was investigated in a sample of seven type I/type I, three type I/non-type I, six type I/untyped, and four untyped unrelated cystinuric patients by RNA single-strand conformation polymorphism (RNA-SSCP). RESULTS: Eight new point mutations (S168X, 765+1G>T, 766-2A>G, R452Q, Y461X, S547W, L564F, and C673W) and seven previously reported mutations were detected. These new mutations increase the number of mutated alleles so far characterized in SLC3A1 to 62. CONCLUSIONS: We have found SLC3A1 mutations in 0.739 of the type I chromosomes studied. The relatively high proportion of uncharacterized type I chromosomes suggests either that there may be mutations not yet found in SLC3A1 or that many of the assigned type I chromosomes in mixed type I/non-type I patients may have mutations in SLC7A9. If the hypothesis is excluded in the future, we believe that a third gene may be involved in cystinuria.  (+info)

Human cystinuria-related transporter: localization and functional characterization. (8/77)

BACKGROUND: Cystinuria has been proposed to be an inherited defect of apical membrane transport systems for cystine and basic amino acids in renal proximal tubules. Although the mutations of the recently identified transporter BAT1/b(0,+)AT have been related to nontype I cystinuria, the function and localization of human BAT1 (hBAT1)/b(0,+)AT have not been well characterized. METHODS: The cDNA encoding hBAT1 was isolated from human kidney. Fluorescence in situ hybridization was performed to map the hBAT1 gene on human chromosomes. Tissue distribution and localization of expression were examined by Northern blot and immunohistochemical analyses. hBAT1 cDNA was transfected to COS-7 cells with rBAT cDNA, and the uptake and efflux of 14C-labeled amino acids were measured to determine the functional properties. The roles of protein kinase-dependent phosphorylation were investigated using inhibitors or activators of protein kinases. RESULTS: The hBAT1 gene was mapped to 19q12-13.1 on the human chromosome, which is the locus of nontype I cystinuria. hBAT1 message was expressed predominantly in kidney. hBAT1 protein was localized in the apical membrane of proximal tubules in human kidney. When expressed in COS-7 cells with a type II membrane glycoprotein rBAT (related to b(0,+)-amino acid transporter), hBAT1 exhibited the transport activity with the properties of amino acid transport system b(0,+), which transported cystine as well as basic and neutral amino acids presumably via a substrate exchange mechanism. BAT1-mediated transport was reduced by the protein kinase A activator and enhanced by the tyrosine kinase inhibitor. CONCLUSIONS: hBAT1 exhibited the properties expected for a transporter subserving the high-affinity cystine transport system in renal proximal tubules. The hBAT1 gene was mapped to the locus of nontype I cystinuria, confirming the involvement of hBAT1 in cystinuria.  (+info)

Cystinuria is a genetic disorder that affects the way the body handles certain amino acids, specifically cystine, arginine, lysine, and ornithine. These amino acids are normally reabsorbed in the kidneys and released into the bloodstream. However, people with cystinuria have a defect in the transport mechanism that causes large amounts of cystine to be excreted in the urine, where it can form stones in the urinary tract. These stones can cause pain, blockages, and infection. Cystinuria is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the defective gene, one from each parent, to have the condition.

Amino acid transport systems are specialized cellular mechanisms responsible for the active transport of amino acids across cell membranes. These systems are essential for maintaining proper amino acid homeostasis within cells and organisms. They consist of several types of transporters that can be categorized based on their energy source, electrochemical gradient, substrate specificity, and functional characteristics.

The term 'basic' in this context typically refers to the fundamental understanding of these transport systems, including their structure, function, regulation, and physiological roles. Amino acid transport systems play a crucial role in various biological processes, such as protein synthesis, neurotransmission, cell signaling, and energy metabolism.

There are two primary types of amino acid transport systems:

1. **Na+-dependent transporters:** These transporters utilize the sodium gradient across the cell membrane to drive the uptake of amino acids. They can be further divided into subtypes based on their substrate specificity and functional properties, such as system A, system ASC, system B0, system B, system L, and system y+.
2. **Na+-independent transporters:** These transporters do not rely on the sodium gradient for amino acid transport. Instead, they use other energy sources like proton gradients or direct coupling to membrane potential. Examples of Na+-independent transporters include system L, system y+, and system x-AG.

Understanding the basic aspects of amino acid transport systems is essential for elucidating their roles in health and disease. Dysregulation of these systems has been implicated in various pathological conditions, such as neurological disorders, cancer, and metabolic diseases.

Cystine is a naturally occurring amino acid in the body, which is formed from the oxidation of two cysteine molecules. It is a non-essential amino acid, meaning that it can be produced by the body and does not need to be obtained through diet. Cystine plays important roles in various biological processes, including protein structure and antioxidant defense. However, when cystine accumulates in large amounts, it can form crystals or stones, leading to conditions such as cystinuria, a genetic disorder characterized by the formation of cystine kidney stones.

Urinary calculi, also known as kidney stones or nephrolithiasis, are hard deposits made of minerals and salts that form inside the urinary system. These calculi can develop in any part of the urinary system, which includes the kidneys, ureters, bladder, and urethra.

The formation of urinary calculi typically occurs when there is a concentration of certain substances, such as calcium, oxalate, uric acid, or struvite, in the urine. When these substances become highly concentrated, they can crystallize and form small seeds that gradually grow into larger stones over time.

The size of urinary calculi can vary from tiny, sand-like particles to large stones that can fill the entire renal pelvis. The symptoms associated with urinary calculi depend on the stone's size, location, and whether it is causing a blockage in the urinary tract. Common symptoms include severe pain in the flank, lower abdomen, or groin; nausea and vomiting; blood in the urine (hematuria); fever and chills; and frequent urge to urinate or painful urination.

Treatment for urinary calculi depends on the size and location of the stone, as well as the severity of symptoms. Small stones may pass spontaneously with increased fluid intake and pain management. Larger stones may require medical intervention, such as extracorporeal shock wave lithotripsy (ESWL), ureteroscopy, or percutaneous nephrolithotomy (PCNL) to break up or remove the stone. Preventive measures include maintaining adequate hydration, modifying dietary habits, and taking medications to reduce the risk of stone formation.

Urinary bladder calculi, also known as bladder stones, refer to the formation of solid mineral deposits within the urinary bladder. These calculi develop when urine becomes concentrated, allowing minerals to crystallize and stick together, forming a stone. Bladder stones can vary in size, ranging from tiny sand-like particles to larger ones that can occupy a significant portion of the bladder's volume.

Bladder stones typically form as a result of underlying urinary tract issues, such as bladder infection, enlarged prostate, nerve damage, or urinary retention. Symptoms may include lower abdominal pain, difficulty urinating, frequent urination, blood in the urine, and sudden, strong urges to urinate. If left untreated, bladder stones can lead to complications like urinary tract infections and kidney damage. Treatment usually involves surgical removal of the stones or using other minimally invasive procedures to break them up and remove the fragments.

I'm sorry for any confusion, but "Libya" is not a medical term. It is a country located in North Africa, known officially as the "State of Libya." If you have any questions about medical terms or concepts, I would be happy to help answer those for you!

Renal aminoacidurias are a group of inherited kidney disorders characterized by the abnormal excretion of amino acids in the urine (aminoaciduria). This condition results from defects in the renal tubular transport systems that are responsible for the reabsorption of amino acids from the filtrate in the kidneys.

There are several types of renal aminoacidurias, each associated with a specific genetic mutation affecting different transporter proteins in the proximal renal tubules. The most common type is cystinuria, which is caused by a defect in the transport system for four amino acids: cystine, ornithine, lysine, and arginine. Other types of renal aminoacidurias include Hartnup disorder, Lowe syndrome, and Dent disease, among others.

The clinical manifestations of renal aminoacidurias vary depending on the specific type and severity of the disorder. Some individuals may be asymptomatic or have only mild symptoms, while others may experience severe complications such as kidney stones, urinary tract infections, neurological symptoms, or growth retardation.

Treatment for renal aminoacidurias typically involves dietary modifications, increased fluid intake, and medications to reduce the risk of kidney stone formation and other complications. In some cases, surgery may be necessary to remove large kidney stones.

Kidney calculi, also known as kidney stones, are hard deposits made of minerals and salts that form inside your kidneys. They can range in size from a grain of sand to a golf ball. When they're small enough, they can be passed through your urine without causing too much discomfort. However, larger stones may block the flow of urine, causing severe pain and potentially leading to serious complications such as urinary tract infections or kidney damage if left untreated.

The formation of kidney calculi is often associated with factors like dehydration, high levels of certain minerals in your urine, family history, obesity, and certain medical conditions such as gout or inflammatory bowel disease. Symptoms of kidney stones typically include severe pain in the back, side, lower abdomen, or groin; nausea and vomiting; fever and chills if an infection is present; and blood in the urine. Treatment options depend on the size and location of the stone but may include medications to help pass the stone, shock wave lithotripsy to break up the stone, or surgical removal of the stone in severe cases.

Neutral amino acid transport systems refer to a group of membrane transporters that facilitate the movement of neutral amino acids across cell membranes. Neutral amino acids are those that have a neutral charge at physiological pH and include amino acids such as alanine, serine, threonine, valine, leucine, isoleucine, methionine, cysteine, tyrosine, phenylalanine, and tryptophan.

There are several different transport systems that have been identified for neutral amino acids, each with its own specificity and affinity for different amino acids. Some of the major neutral amino acid transport systems include:

1. System A: This transporter preferentially transports small, neutral amino acids such as alanine, serine, and threonine. It is found in many tissues, including the intestines, kidneys, and brain.
2. System B0+: This transporter preferentially transports large, neutral amino acids such as leucine, isoleucine, valine, methionine, and phenylalanine. It is found in many tissues, including the intestines, kidneys, and brain.
3. System L: This transporter preferentially transports large, neutral amino acids such as leucine, isoleucine, valine, methionine, and phenylalanine. It is found in many tissues, including the intestines, kidneys, and brain.
4. System y+: This transporter preferentially transports cationic amino acids such as lysine and arginine, but it can also transport some neutral amino acids. It is found in many tissues, including the intestines, kidneys, and brain.
5. System b0,+: This transporter preferentially transports cationic amino acids such as lysine and arginine, but it can also transport some neutral amino acids. It is found in many tissues, including the intestines, kidneys, and brain.

These transport systems play important roles in maintaining amino acid homeostasis in the body, as well as in various physiological processes such as protein synthesis, neurotransmitter synthesis, and cell signaling. Dysregulation of these transport systems has been implicated in several diseases, including cancer, neurological disorders, and metabolic disorders.

Diamino acids are a type of modified amino acids that contain two amino groups (-NH2) in their side chain. In regular amino acids, the side chain is composed of a specific arrangement of carbon, hydrogen, oxygen, and sometimes sulfur atoms. However, in diamino acids, one or both of the hydrogen atoms attached to the central carbon atom (alpha carbon) are replaced by amino groups.

There are two types of diamino acids: symmetric and asymmetric. Symmetric diamino acids have identical side chains on both sides of the alpha carbon atom, while asymmetric diamino acids have different side chains on each side.

Diamino acids play a crucial role in various biological processes, such as protein synthesis, cell signaling, and neurotransmission. They can be found naturally in some proteins or can be synthesized artificially for use in research and medical applications.

It is important to note that diamino acids are not one of the twenty standard amino acids that make up proteins. Instead, they are considered non-proteinogenic amino acids, which means they are not typically encoded by DNA and are not directly involved in protein synthesis. However, some modified forms of diamino acids can be found in certain proteins as a result of post-translational modifications.

Urolithiasis is the formation of stones (calculi) in the urinary system, which includes the kidneys, ureters, bladder, and urethra. These stones can be composed of various substances such as calcium oxalate, calcium phosphate, uric acid, or struvite. The presence of urolithiasis can cause symptoms like severe pain in the back or side, nausea, vomiting, fever, and blood in the urine. The condition can be managed with medications, increased fluid intake, and in some cases, surgical intervention may be required to remove the stones.

Hartnup disease is a rare autosomal recessive disorder of amino acid transport, characterized by the excretion of large amounts of neutral amino acids in the urine and pellagra-like symptoms. It is caused by mutations in the SLC6A19 gene, which encodes for the B0AT1 protein, a neutral amino acid transporter in the brush border of the small intestine and kidney proximal tubule. The disease affects the absorption and reabsorption of neutral amino acids, leading to their deficiency in the body. Symptoms can include skin rashes, cerebellar ataxia, psychiatric symptoms, and episodic neurological symptoms that respond to treatment with nicotinamide (a form of vitamin B3). The diagnosis is confirmed by detecting increased excretion of neutral amino acids in the urine. Treatment typically involves dietary supplementation with affected amino acids and nicotinamide.

There is no medical definition for "dog diseases" as it is too broad a term. However, dogs can suffer from various health conditions and illnesses that are specific to their species or similar to those found in humans. Some common categories of dog diseases include:

1. Infectious Diseases: These are caused by viruses, bacteria, fungi, or parasites. Examples include distemper, parvovirus, kennel cough, Lyme disease, and heartworms.
2. Hereditary/Genetic Disorders: Some dogs may inherit certain genetic disorders from their parents. Examples include hip dysplasia, elbow dysplasia, progressive retinal atrophy (PRA), and degenerative myelopathy.
3. Age-Related Diseases: As dogs age, they become more susceptible to various health issues. Common age-related diseases in dogs include arthritis, dental disease, cancer, and cognitive dysfunction syndrome (CDS).
4. Nutritional Disorders: Malnutrition or improper feeding can lead to various health problems in dogs. Examples include obesity, malnutrition, and vitamin deficiencies.
5. Environmental Diseases: These are caused by exposure to environmental factors such as toxins, allergens, or extreme temperatures. Examples include heatstroke, frostbite, and toxicities from ingesting harmful substances.
6. Neurological Disorders: Dogs can suffer from various neurological conditions that affect their nervous system. Examples include epilepsy, intervertebral disc disease (IVDD), and vestibular disease.
7. Behavioral Disorders: Some dogs may develop behavioral issues due to various factors such as anxiety, fear, or aggression. Examples include separation anxiety, noise phobias, and resource guarding.

It's important to note that regular veterinary care, proper nutrition, exercise, and preventative measures can help reduce the risk of many dog diseases.

Surgical instruments are specialized tools or devices that are used by medical professionals during surgical procedures to assist in various tasks such as cutting, dissecting, grasping, holding, retracting, clamping, and suturing body tissues. These instruments are designed to be safe, precise, and effective, with a variety of shapes, sizes, and materials used depending on the specific surgical application. Some common examples of surgical instruments include scalpels, forceps, scissors, hemostats, retractors, and needle holders. Proper sterilization and maintenance of these instruments are crucial to ensure patient safety and prevent infection.

Blood specimen collection is the process of obtaining a sample of blood from a patient for laboratory testing and analysis. This procedure is performed by trained healthcare professionals, such as nurses or phlebotomists, using sterile equipment to minimize the risk of infection and ensure accurate test results. The collected blood sample may be used to diagnose and monitor various medical conditions, assess overall health and organ function, and check for the presence of drugs, alcohol, or other substances. Proper handling, storage, and transportation of the specimen are crucial to maintain its integrity and prevent contamination.

  • In 1908, Sir Archibald Garrod identified cystinuria as one of the original "inborn errors of metabolism. (medscape.com)
  • Cystinuria is an inherited autosomal recessive disease characterized by high concentrations of the amino acid cystine in the urine, leading to the formation of cystine stones in the kidneys, ureters, and bladder. (wikipedia.org)
  • Cystinuria is an autosomal recessive disease, which means that the defective gene responsible for the disease is located on an autosome, and two copies of the defective gene (one inherited from each parent) are required in order to be born with the disease. (wikipedia.org)
  • Cystinuria is an autosomal-recessive defect in reabsorptive transport of cystine and the dibasic amino acids ornithine, arginine, and lysine from the luminal fluid of the renal proximal tubule and small intestine. (medscape.com)
  • In 1955, Harris et al reported the complex autosomal-recessive pattern of inheritance of cystinuria. (medscape.com)
  • Canine cystinuria can be of three types - Type I (autosomal recessive), Type II (autosomal dominant), and Type III (formerly known as non-Type I). (bullsofcrown.nl)
  • Cystinuria is an inherited autosomal recessive disorder of the kidney that is the result of an inability to reabsorb cystine from the urine. (ucbraid.org)
  • Cystinuria is an autosomal recessive disease characterized by impaired transport of cystine and dibasic amino acids in the proximal renal tubule, resulting in the formation of cystine stones. (chikd.org)
  • However, once a stone is formed, signs and symptoms can occur: Nausea Flank pain Hematuria Urinary tract infections Rarely, acute or chronic kidney disease People with cystinuria pass stones monthly, weekly, or daily, and need ongoing care. (wikipedia.org)
  • Although signs and symptoms are rare, there are some directly and indirectly associated with cystinuria. (wikipedia.org)
  • To have the symptoms of cystinuria, you must inherit the faulty gene from both parents. (medlineplus.gov)
  • For this reason, neutering a male cystinuria-positive Bulldog will prevent his body from forming stones or developing symptoms. (bullsofcrown.nl)
  • Symptoms of cystinuria, most commonly renal colic, may occur in infants but usually appear between ages 10 and 30. (msdmanuals.com)
  • Cystine stones constitute a major health challenge for affected individuals with cystinuria because of the frequent recurrence of painful symptoms and the current absence of effective, patient-accepting treatment. (ucbraid.org)
  • Used to treat Wilson's disease, cystinuria, severe rheumatoid arthritis and chronic active hepatitis. (e-lactancia.org)
  • It is used to treat Wilson's disease and cystinuria. (clevelandclinic.org)
  • copper supplements · certain medicines for treating bacterial infection including cefalexin, ceftibuten, quinolones (e.g. ciprofloxacin and levofloxacin) and tetracyclines (e.g. oxytetracycline and tetracycline) · penicillamine, which is used to treat rheumatism and certain metabolic disorders such as Wilson's disease and cystinuria. (who.int)
  • The diagnosis of cystinuria is readily made by stone analysis, microscopic examination of the urine, and 24-hour urine testing. (medscape.com)
  • Cystinuria is an inherited metabolic disease that is caused by defects in two genes, SLC3A1 and SLC7A9, which result in a renal reabsorptive defect of cystine and other dibasic amino acids, including ornithine, arginine, and lysine. (qxmd.com)
  • Cystinuria is an inherited defect of the renal tubules in which reabsorption of cystine (the homodimer of the amino acid cysteine ) is impaired, urinary excretion is increased, and cystine stones form in the urinary tract. (msdmanuals.com)
  • Cystinuria is an inherited disorder of renal transport characterised by high urine concentrations of cystine and other similar amino acids (ornithine, lysine, arginine). (eurovetgene.com)
  • Here we report a case of cystinuria with multiple renal stones confirmed by genetic mutational analysis. (chikd.org)
  • Cystinuria is a disorder characterized by cystine stones in the kidney, ureter, and bladder. (medlineplus.gov)
  • The hypothesis suggests that administration of this drug to patients with cystinuria will introduce sufficient glucose into the urine to prevent or reverse the formation of cystine stones. (ucbraid.org)
  • Cystine stones form in people who have an inherited condition called cystinuria . (healthline.com)
  • Cystine Stones These can develop in people who have a condition called cystinuria, in which the urine contains too much of the amino acid cystine. (everydayhealth.com)
  • People with cystinuria have a genetic defect that interferes with this process. (medlineplus.gov)
  • In recent years, understanding of the genetic and molecular components of cystinuria has advanced. (medscape.com)
  • Genetic studies of DNA from families with cystinuria reveal a defective gene located on chromosome 2. (medscape.com)
  • Because it is a genetic disease, there is no concrete way to prevent cystinuria in Bulldogs. (bullsofcrown.nl)
  • A retrospective chart review for cystinuria patients from the genetic and nephrology divisions between 2010 to 2015. (qxmd.com)
  • Cystinuria has wide genetic heterogeneity with a poor genotype/phenotype correlation. (qxmd.com)
  • Women with cystinuria who desire pregnancy should seek genetic counseling, and management of their disease should begin prior to pregnancy. (medscape.com)
  • Urine odor in cystinuria has a smell of rotten eggs due to the increase in cystine. (wikipedia.org)
  • Cystinuria is characterized by the inadequate reabsorption of cystine in the proximal convoluted tubules after the filtering of the amino acids by the kidney's glomeruli, thus resulting in an excessive concentration of this amino acid in the urine. (wikipedia.org)
  • Cystinuria is caused by too much cystine in the urine. (medlineplus.gov)
  • Cystinuria is a rare condition in which stones made from an amino acid called cysteine form in the kidney, ureter, and bladder. (medlineplus.gov)
  • [ 9 ] showed abnormal excretion of the dibasic amino acids lysine, arginine, and ornithine in persons with cystinuria. (medscape.com)
  • [ 10 ] In 1961, Milne et al demonstrated reduced intestinal absorption of dibasic amino acids in persons with cystinuria. (medscape.com)
  • Cystinuria is an inherited condition that prevents the body's normal processing of an amino acid named "cystine" which can form rock hard cystine kidney stones. (cystinuria.org)
  • Cystinuria is a hereditary condition in which the kidney is unable to process cystine, an amino acid, correctly. (bullsofcrown.nl)
  • Cystinuria was originally classified according to urinary excretion of cystine and dibasic amino acids in obligate carriers. (msdmanuals.com)
  • Cystinuria-specific rBAT(R365W) mutation reveals two translocation pathways in the amino acid transporter rBAT-b0,+AT. (irbbarcelona.org)
  • citation needed] Cystinuria is caused by mutations in the SLC3A1 and SLC7A9 genes. (wikipedia.org)
  • Just one out of three mutations is enough to cause cystinuria. (eurovetgene.com)
  • Mutations that have been discovered to date are not responsible for all cases of Cystinuria in cats. (eurovetgene.com)
  • Mutations in rBAT cause cystinuria type A, whereas mutations in b(0,+)AT cause cystinuria type B. b(0,+)AT is the catalytic subunit, whereas it is believed that rBAT helps the routing of the rBAT/b(0,+)AT heterodimeric complex to the plasma membrane. (irbbarcelona.org)
  • Cystinuria is a cause of recurrent kidney stones. (wikipedia.org)
  • Although cystinuria accounts for only about 1-2% of kidney stones in adults, this disorder can result in significant morbidity beginning at a young age, with more frequent stone events and need for surgical intervention than in other urolithiasis disorders, and potentially faster progression to kidney insufficiency. (medscape.com)
  • [ 2 ] On average, individuals with untreated cystinuria experience one new stone every year and require a surgical procedure to remove the stones every 3 years. (medscape.com)
  • Although dogs with cystinuria have a very high chance of forming stones, not all of them do. (bullsofcrown.nl)
  • No significant clinical differences were detected in this study between type A (SLC3A1 variants) and type B cystinuria (SLC7A9 variant). (qxmd.com)
  • To identify some of the issues early, a veterinarian may recommend regular cystinuria and cardiac exams for this breed of dog. (petmd.com)
  • Two cases were diagnosed based on clinical information, biochemical testing and a positive family history as all of the molecular testing for cystinuria was negative. (qxmd.com)
  • 11144 the veteran had cystinuria before the clinical onset of the condition under consideration. (dva.gov.au)
  • 11145 - the veteran has established the causal connection between the cystinuria and VEA service for the clinical onset of the condition under consideration. (dva.gov.au)
  • 11147 - the veteran has established the causal connection between the cystinuria and eligible service for the clinical onset of the condition under consideration. (dva.gov.au)
  • By middle age, the average cystinuria patient will have undergone seven surgical procedures. (medscape.com)
  • She was known to have cystinuria and had already undergone extracorporeal shock wave treatment with concrement removal in 2004. (cdc.gov)
  • [ 12 ] In 1963, Crawhall et al first used penicillamine to treat patients with cystinuria. (medscape.com)
  • Intestinal absorption of oligopeptides in cystinuria. (nih.gov)
  • Straining to pee is the most visible signs of Cystinuria in Bulldogs. (bullsofcrown.nl)
  • citation needed] The overall prevalence of cystinuria is approximately 1 in 7,000 neonates (from 1 in 2,500 neonates in Libyan Jews to 1 in 100,000 among Swedes). (wikipedia.org)
  • [ 14 ] In 1997, Bisceglia et al identified type III cystinuria on band 19q13.1. (medscape.com)
  • Cystinuria in Bulldogs and other Mastiff breeds is mostly of the Type III category. (bullsofcrown.nl)
  • Aside from Bulldogs, Mastiff and Bulldog breeds such as the English Mastiff, the Cane Corso, the Italian Mastiff, and the French Bulldog are also prone to this type of cystinuria. (bullsofcrown.nl)
  • Sadly, there is no cure for cystinuria because the condition is embedded in your Bulldog's genes and bodily chemicals. (bullsofcrown.nl)
  • 11159 there is some evidence that cystinuria may be a factor in the development of the condition under consideration. (dva.gov.au)
  • The International Cystinuria Foundation is a 501(c)3 non-profit organization created exclusively for educational, scientific and charitable causes. (cystinuria.org)
  • About one in every 7000 people have cystinuria. (medlineplus.gov)
  • As part of "Cystinuria Awareness Day" we would like to post stories of real people, and how Cystinuria has affected your life. (cystinuria.org)
  • Vets prescribe four tests to detect cystinuria in Bulldogs or any other dog. (bullsofcrown.nl)
  • High-affinity system: This system is affected in persons with cystinuria. (medscape.com)
  • Conclusion : La lithiase submandibulaire bilatérale est un fait clinique rare mais qu'il faut savoir rechercher même en cas de lithiase submandibulaire isolée. (bvsalud.org)
  • Negative results from urinalysis and nitroprusside spot test do not mean that your Bulldog is free from cystinuria. (bullsofcrown.nl)
  • Delineation of cystinuria in Saudi Arabia: A case series. (qxmd.com)
  • When the effects of cystinuria start to show, your pet may experience the following. (bullsofcrown.nl)

No images available that match "cystinuria"